IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: a Northern Ireland observational study

Louise Robertson, RK Price, Julie Moore, Grace Curry, John Farnan, Amy Black, Kevin Blighe, M. Andrew Nesbit, James McLaughlin, Tara C. B. Moore

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
47 Downloads (Pure)

Abstract

BackgroundThis study evaluates spike protein IgG antibody response following Oxford-AstraZeneca COVID-19 vaccination using the AbC-19™ lateral flow device.MethodsPlasma samples were collected from n = 111 individuals from Northern Ireland. The majority were >50 years old and/or clinically vulnerable. Samples were taken at five timepoints from pre-vaccination until 6-months post-first dose.Results20.3% of participants had detectable IgG responses pre-vaccination, indicating prior COVID-19. Antibodies were detected in 86.9% of participants three weeks after the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% three weeks post-second vaccine. At 6-months post-first dose, this decreased to 90.5%. At all timepoints, previously infected participants had significantly higher antibody levels than those not previously infected.ConclusionThis study demonstrates that strong anti-spike protein antibody responses are evoked in almost all individuals that receive two doses of Oxford-AstraZeneca vaccine, and which largely persist beyond six months after first vaccination.
Original languageEnglish
Pages (from-to)2535-2539
Number of pages5
JournalVaccine
Volume40
Issue number18
Early online date3 Mar 2022
DOIs
Publication statusPublished (in print/issue) - 20 Apr 2022

Bibliographical note

Funding Information:
The study was funded by Abingdon Health, United Kingdom who also provided the AbC-19™ testing devices. Abingdon Health had no other involvement in the study.

Publisher Copyright:
© 2022 The Authors

Keywords

  • Adenovirus vector-based vaccine
  • Antibody response
  • COVID-19
  • COVID-19 vaccination
  • Oxford-AstraZeneca ChAdOx1
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: a Northern Ireland observational study'. Together they form a unique fingerprint.

Cite this